mTOR and PTEN expression in non-small cell lung cancer: Analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry

Surgery Today

Volumn 42, Issue 5, 2012, Pages 419-425

  Wang, Liang ^a   Yue, Wentao ^a   Zhang, Lina ^a   Zhao, Xiaoting ^a   Wang, Yue ^a   Xu, Shaofa ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

mTOR; Non small cell lung cancer; Prognosis; PTEN

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SURVIVAL RATE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84862686050     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-011-0028-1     Document Type: Article

References (12)

1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;59:225-49.
2. Toloza EM, Damico TA. Targeted therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2005;17:199-204.
3. Pal SK, Figlin RA, Reckamp KL. The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 2008;9:340-5.
4. Hay N, Sonenberg N. Upstream and downstream of mTOR. Gene Dev. 2004;18:1926-45.
5. Steelman LS, Bertrrand FE, McCubrey JA. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets. 2004;8:537-50.
6. Han W, Ming M, He TC, He YY. Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem. 2010; 285:11369-77.
7. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschläger M. The mTOR pathway and its role in human genetic diseases. Mutat Res. 2008;659:284-92.
8. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science. 1997;275: 1943-7.
9. Iyoda A, Hiroshima K, Moriya Y, Yoshida S, Suzuki M, Shibuya K, et al. Predictors of postoperative survival in patients with locally advanced non-small cell lung carcinoma. Surg Today. 2010;40(8):725-8.
10. Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A, et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res. 2006;12:710-7.
11. Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, et al. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res. 2007;13:4795-9.
12. Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, Viswanathan A, et al. PTEN and phosphorylated AKT expression and prognosis in early-and late-stage non-small cell lung cancer. Oncol Rep. 2007;17(4):853-7.